Clinical Trials
34 trialsAntiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NRG Oncology
THUNDER
Cancer Research Antwerp
Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients
Tianjin Medical University Cancer Institute and Hospital
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
Shanghai Jiao Tong University School of Medicine
OCTASUR
Ukrainian Society of Clinical Oncology
ADAPT
West German Study Group
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Shengjing Hospital
Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage
Zhongnan Hospital
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature
Fudan University
Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma
Huai'an First People's Hospital
CHANGE
Shanghai University of Traditional Chinese Medicine
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
Shanghai Jiao Tong University School of Medicine
A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
Spanish Oncology Genito-Urinary Group
RAMSES/FLOT7
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer
Shengjing Hospital
Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
RusGCG-01
Blokhin's Russian Cancer Research Center
PREDIX HER2
Karolinska University Hospital
A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer
Air Force Military Medical University, China
TENDENCY
Hebei Medical University Fourth Hospital
5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
Krankenhaus Nordwest
Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
Qingdao Central Hospital
NeoIntercal
AIO-Studien-gGmbH
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
Shandong Cancer Hospital and Institute
Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy
Shandong Cancer Hospital and Institute
Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer
Shanghai Zhongshan Hospital
Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma
Tehran University of Medical Sciences
Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)
Columbia University
Evaluation of Postoperative Radiotherapy and Concurrent Chemotherapy Effectiveness in Cervical Cancer
Air Force Military Medical University, China
Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction
Medical University of Lublin
Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer
Fudan University